Scilex Holding (SCLX) Change in Accured Expenses (2021 - 2026)

Scilex Holding (SCLX) posted quarterly Change in Accured Expenses of -$7.8 million for Q1 2026, down 1028.06% year-over-year from $841000.0 in Q1 2025, and down 2563.82% on a QoQ basis from -$293000.0 in Q4 2025.

Scilex Holding (SCLX) Change in Accured Expenses (2021 - 2026) Analysis & Trends

Scilex Holding (SCLX) has reported Change in Accured Expenses for 6 consecutive years, with -$7.8 million the latest figure, recorded in Q1 2026.

  • In Q1 2026, Change in Accured Expenses fell 1028.06% year-over-year to -$7.8 million; the TTM figure through Mar 2026 stood at $6.0 million (up 170.51% YoY), while the FY2025 annual figure was $14.6 million, up 278.78% from the prior year.
  • Change in Accured Expenses came in at -$7.8 million for Q1 2026 at Scilex Holding, down from -$293000.0 in the prior quarter.
  • The five-year high for Change in Accured Expenses was $14.3 million in Q3 2025, with the low at -$10.6 million in Q4 2024.
  • Average Change in Accured Expenses over 5 years is $32176.5, with a median of -$126000.0 recorded in 2022.
  • Across the five-year window, Change in Accured Expenses plunged 19597.95% in 2022 and soared 29625.0% in 2023, its largest moves.
  • Year by year, Change in Accured Expenses stood at $981000.0 in 2022, then tumbled by 427.73% to -$3.2 million in 2023, then tumbled by 230.64% to -$10.6 million in 2024, then surged by 97.24% to -$293000.0 in 2025, then sank by 2563.82% to -$7.8 million in 2026.
  • According to Business Quant data, Change in Accured Expenses over the past three periods registered -$7.8 million, -$293000.0, and $14.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Accured Expenses (Qtr)
1 Eli Lilly 1,066.16 Bn 1,060.88 Bn 16.22 Bn -
2 Johnson & Johnson 611.69 Bn 589.64 Bn 15.96 Bn -629.00 Mn
3 AbbVie 444.34 Bn 434.99 Bn 10.78 Bn -1.59 Bn
4 Astrazeneca 284.94 Bn 277.05 Bn 12.61 Bn -
5 Merck 224.23 Bn 218.58 Bn 12.09 Bn -
6 Amgen 195.12 Bn 183.08 Bn 5.87 Bn -75.00 Mn
7 Gilead Sciences 156.45 Bn 148.73 Bn 5.52 Bn -702.00 Mn
8 Pfizer 136.01 Bn 123.24 Bn -1.21 Bn -
9 Novartis Ag 113.45 Bn 113.67 Bn - -
10 Scilex Holding 54.30 Mn -95.62 Mn 4.15 Mn -7.81 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -7.81 Mn
Mar 31, 2026 -7.81 Mn
Dec 31, 2025 -293,000.00
Dec 31, 2025 -293,000.00
Sep 30, 2025 14.30 Mn
Sep 30, 2025 14.30 Mn
Jun 30, 2025 -242,000.00
Jun 30, 2025 -242,000.00
Mar 31, 2025 841,000.00
Mar 31, 2025 841,000.00
Dec 31, 2024 -10.63 Mn
Dec 31, 2024 -10.63 Mn
Sep 30, 2024 1.99 Mn
Sep 30, 2024 1.99 Mn
Jun 30, 2024 -650,000.00
Jun 30, 2024 -650,000.00
Mar 31, 2024 1.12 Mn
Mar 31, 2024 1.12 Mn
Dec 31, 2023 -3.22 Mn
Dec 31, 2023 -3.22 Mn